Drug Profile

Research programme: kynurenine-degrading enzyme - Ikena Oncology

Latest Information Update: 28 Jan 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kyn Therapeutics
Developer Ikena Oncology
Class Antineoplastics; Enzymes; Immunotherapies
Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Kynurenine modulators; Tryptophan oxygenase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Cancer

Most Recent Events

28 Jan 2022 No recent reports of development identified for preclinical development in Cancer in USA
03 Dec 2019 Kyn Therapeutics is now called Ikena Oncology
20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com